Doha: US health authorities approved the first blood test for diagnosing Alzheimer's disease, potentially enabling patients to begin medication earlier to slow the progression of this neurodegenerative disorder. According to Qatar News Agency, the test, developed by Fujirebio Diagnostics, measures the levels of two proteins in the blood linked to the presence of beta-amyloid plaques in the brain, a hallmark of Alzheimer's disease. Until now, these plaques could only be detected through brain scans or cerebrospinal fluid analysis. The test has been clinically approved for patients showing signs of cognitive decline. Michelle Tarver from the US Center for Devices and Radiological Health stated that the approval of this new test marks a significant milestone in Alzheimer's diagnosis, making it easier and more accessible to patients in the United States at an early stage of the disease. Marty Makary from the US Food and Drug Administration added that Alzheimer's affects a very large number of people, more tha n breast and prostate cancer combined. Ten percent of people aged 65 and older suffer from Alzheimer's, and this number is expected to double by 2050, expressing hope that new medical products like this test will help patients. Alzheimer's is the most common form of dementia, with symptoms worsening over time, leading to gradual loss of memory and independence. Currently, two approved drugs - Lecanemab and Donanemab - target amyloid plaques and moderately slow cognitive decline but do not cure the disease.